SCHEMBL3057233

SCHEMBL3057233

CCc1noc(C2CCCN(c3nncc4cc(OC)c(OC)cc34)C2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.46
EPHA2 P29317 2/20 0.41
EPHB4 P54760 2/20 0.41
ERBB2 P04626 1/20 0.41
PDE3A Q14432 2/20 0.41
KDR P35968 1/20 0.40
LMNA P02545 2/20 0.39
ALDH1A1 P00352 1/20 0.39
RAB9A P51151 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.38
GAA P10253 1/20 0.38
MAPK1 P28482 1/20 0.38
TSHR P16473 2/20 0.37
PRKDC P78527 1/20 0.37
MEN1 O00255 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3059738 0.89 PDE10A (0.44) PDE10AEPHA2EPHB4ERBB2KDR
SCHEMBL3056007 0.88 ALDH1A1 (0.43) PDE10AEPHA2EPHB4ERBB2PDE3A
SCHEMBL3057235 0.88 PRKDC (0.48) PDE10APDE3ALMNAALDH1A1NPC1
SCHEMBL3055282 0.85 PDE10A (0.46) PDE10APDE3ALMNAALDH1A1RAB9A
SCHEMBL3051749 0.82 PDE10A (0.50) PDE10APDE3A
SCHEMBL3059501 0.81 PDE10A (0.48) PDE10APDE3A
SCHEMBL3055275 0.80 PDE10A (0.48) PDE10APDE3AALDH1A1RAB9ANPC1
SCHEMBL3059879 0.80 PDE10A (0.46) PDE10APDE3ALMNAALDH1A1GAA
SCHEMBL3062103 0.78 PDE10A (0.44) PDE10APDE3A
SCHEMBL3052396 0.77 PDE10A (0.70) PDE10APDE3ALMNAALDH1A1PRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100222353-A1 AMINOPHTHALAZINE DERIVATIVE COMPOUNDS PFIZER PRODUCTS INC. (US) 2010-09-02 US claimed
EP-1981868-A2 AMINOPHTHALAZINE DERIVATIVE COMPOUNDS Pfizer Products Inc. (US) 2008-10-22 EP claimed
WO-2007085954-A2 AMINOPHTHALAZINE DERIVATIVE COMPOUNDS PFIZER PRODUCTS INC. (US) 2007-08-02 WO claimed
US-20100222353-A1 AMINOPHTHALAZINE DERIVATIVE COMPOUNDS PFIZER PRODUCTS INC. (US) 2010-09-02 US disclosed
EP-1981868-A2 AMINOPHTHALAZINE DERIVATIVE COMPOUNDS Pfizer Products Inc. (US) 2008-10-22 EP disclosed
WO-2007085954-A2 AMINOPHTHALAZINE DERIVATIVE COMPOUNDS PFIZER PRODUCTS INC. (US) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222353-A1 AMINOPHTHALAZINE DERIVATIVE COMPOUNDS PDE12, PDE5A, PDE2A PDE10A 6/4885EPHA2 4418/4885EPHB4 3417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.